

## Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City

Vaccination against SARS-CoV-2 is crucial for patients with systemic rheumatic diseases (SRDs), who may be at increased risk of severe outcomes post-COVID-19.<sup>1</sup> However, as patients with SRDs were not included in the mRNA vaccine trials (ie, Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273)), no data exist regarding whether these vaccines might trigger SRD flares. Sparse data suggest that other vaccines may be associated with SRD flares,<sup>2,3</sup> possibly from molecular mimicry triggering immune activation or non-specific adjuvant effects. As SRD flares are associated with disease deterioration, increased flares could have serious clinical implications.<sup>4</sup>

We report the interim results of a web-based survey evaluating SRD flare incidence post-SARS-CoV-2 vaccine. The survey was e-mailed 5 March 2021 to 3545 outpatients with SRDs seen at a large rheumatology division in New York City. ICD-10 algorithms were used to identify SRDs (online supplemental material). A self-reported disease flare was defined as 'a sudden worsening of your rheumatology condition or arthritis' within 2 weeks of the vaccine.

As of 12 April 2021, out of 1483 respondents (41.8% response rate), 1101 patients (74.2%) with SRDs reported receiving at least one dose of a SARS-CoV-2 vaccine and provided flare data (mean age: 60.8 years (14.2 years); 80.6% female; 86.0% White and 5.7% Hispanic/Latinx ethnicity). Five hundred and ninety seven patients (54.2%) received Pfizer vaccine, 483 (43.9%) received Moderna vaccine, 16 (1.5%) received Janssen vaccine and 3 (0.3%) received AstraZeneca vaccine. A total of 202 SRD flares were reported by 165 patients (14.9%). History of suspected/confirmed COVID-19 occurred in 7.9% with SRD flare and 6.7% without SRD flare. Mean age of patients reporting an SRD flare was 59.6 years (13.9 years) versus 61.0 years (14.2 years) in the non-flare group; the majority of both groups were female (89.7% vs 80.0%), White (88.5% vs 85.6%) and non-Hispanic/Latinx (95.2% vs 92.2%). 15.9% of patients receiving Moderna vaccine and 14.2% receiving Pfizer vaccine reported SRD flares.

Of the patients receiving either Pfizer or Moderna vaccines, 654 (59.4%) had received both doses. Of these patients, 113 (17.0%) flared, 26 (23.0%) flared only after the first dose, 48 (42.5%) flared only after the second dose and 37 (32.7%) flared after both doses. Flares after the first and second dose of Pfizer vaccine were 10.3% vs 10.9%, and flares after the first and second dose of Moderna vaccine were 9.6% vs 16.3%, respectively.

Both the flare and non-flare groups used medications for prevention and treatment of vaccine side effects (table 1). Most SRD flares were characterised as moderate to severe (57.3% after first vs 62.4% after second dose), and as qualitatively 'typical' SRD flares (70.9% after first dose vs 68.2% after second dose). Flares were predominantly reported as joint pain, joint swelling, muscle aches and fatigue (table 1). While 27.7% of flares started 1 day after vaccination, 61.4% began after 2–7 days and 10.9% occurred more than 7 days later (table 1). Most SRD flares resolved within 7 days of onset, but 26.2% lasted for 8–21 days and 8.9% for >21 days.

Interim data from our cohort demonstrate that >85% of patients did not report an SRD flare post-SARS-CoV-2

**Table 1** Vaccine and flare characteristics in outpatients with systemic rheumatic diseases, stratified by flare status post-COVID-19 vaccination

	First dose vaccine N=1101		Second dose vaccine* N=626	
	Flare N=117 (10.4%)	No Flare N=984 (87.5%)	Flare N=85 (13.6%)	No Flare N=541 (86.4%)
<b>Vaccine manufacturer, N%</b>				
Pfizer	67 (57.3%)	530 (53.9%)	35 (41.2%)	285 (52.7%)
Moderna	47 (40.2%)	436 (44.3%)	50 (58.8%)	256 (47.3%)
Janssen	3 (2.6%)	13 (1.3%)	N/A	N/A
AstraZeneca	0 (0%)	3 (0.3%)	0 (0%)	0 (0%)
Other†	0	1 (0.1%)	0	0
Missing	0	1 (0.1%)	0	0
<b>Medications taken for prevention of COVID-19 vaccine side effects (prior to vaccine) (N, %)<sup>‡</sup></b>				
No medications	104 (88.9%)	911 (92.6%)	73 (85.9%)	502 (92.8%)
Benadryl	7 (6.0%)	20 (2.0%)	2 (2.4%)	13 (2.4%)
Corticosteroids	2 (1.7%)	7 (0.7%)	3 (3.5%)	4 (0.7%)
Acetaminophen	4 (3.4%)	29 (3.0%)	7 (8.2%)	24 (4.4%)
NSAIDs/CoX-2 inhibitors	4 (3.4%)	22 (2.2%)	1 (1.2%)	11 (2.0%)
<b>Medications taken for treatment of COVID-19 vaccine side effects (after vaccine) (N, %)<sup>‡</sup></b>				
No medications	64 (54.7%)	748 (76.0%)	26 (30.6%)	310 (57.3%)
EpiPen	1 (0.9%)	0 (0%)	0 (0%)	0 (0%)
Benadryl	7 (6.0%)	10 (1.0%)	4 (4.7%)	13 (2.4%)
Corticosteroids	6 (5.1%)	3 (0.3%)	4 (4.7%)	5 (0.9%)
Acetaminophen	29 (24.8%)	152 (15.5%)	36 (42.4%)	166 (30.7%)
NSAIDs/CoX-2 inhibitors	25 (21.4%)	82 (8.3%)	31 (36.5%)	76 (14.1%)
<b>Flare severity (N, %)</b>				
Mild	50 (42.7%)		32 (37.7%)	
Moderate	49 (41.9%)		44 (51.8%)	
Severe	18 (15.4%)		9 (10.6%)	
<b>Flare described as 'typical' (N, %)</b>				
Yes	83 (70.9%)		58 (68.2%)	
No	18 (15.4%)		16 (18.8%)	
Not sure	16 (13.7%)		11 (12.9%)	
<b>Flare symptoms (N, %)<sup>‡</sup></b>				
Fever	6 (5.1%)		9 (10.6%)	
Joint pain	98 (83.8%)		74 (87.1%)	
Joint swelling	56 (47.9%)		38 (44.7%)	
Skin rash	14 (12.0%)		10 (11.8%)	
Fatigue	62 (53.0%)		57 (67.1%)	
Muscle aches	57 (48.7%)		48 (56.5%)	
Other§	16 (13.7%)		11 (12.9%)	
<b>Number of days after vaccine when flare started (N, %)</b>				
1 day	30 (25.6%)		26 (30.6%)	
2–3 days	39 (33.3%)		26 (30.6%)	
4–7 days	35 (29.9%)		24 (28.2%)	
>7 days	13 (11.1%)		9 (10.6%)	
<b>Length of flare (N, %)</b>				
1 day	7 (6.0%)		2 (2.4%)	
2–4 days	23 (19.7%)		40 (47.1%)	
5–7 days	41 (35.0%)		16 (18.8%)	
8–21 days	28 (23.9%)		25 (29.4%)	
>21 days	18 (15.4%)		0 (0%)	
Missing	0		2 (2.4%)	

Flare defined as self-reported 'sudden worsening of rheumatology condition or arthritis' within 2 weeks of COVID-19 vaccination.

\*654 patients reported receiving 2/2 vaccine doses, but 28 of these patients did not respond to second dose flare questions.

†One participant reported receiving Sinovac vaccine from China.

‡Rows not mutually exclusive.

§Other flare symptoms indicated by patients at first COVID-19 vaccine dose: paresthesias, swelling in face or feet, 'brain fog', muscle spasms, psoriasis rash, migraines. Other symptoms at second vaccine dose: paresthesias, swelling in face or feet, and muscle spasms.

CoX-2, cyclooxygenase-2; NSAIDs, nonsteroidal anti-inflammatory drugs.

vaccination. This information is reassuring and can help inform vaccine decision-making for patients with SRDs. Although we did not collect laboratory studies, most SRD flares were described as 'typical', suggesting these symptoms are not vaccine's adverse effects being misreported as disease flares. However, when patients did flare, the majority of flares were reported as moderate to severe, with some lasting >3 weeks. Therefore, it will be important to follow these patients prospectively, as well as to perform analyses which incorporate potential confounders to identify predictors of SRD flares post-vaccination. Whether vaccine manufacturer is an independent predictor of SRD flare remains to be determined.

Medha Barbhैया<sup>1,2</sup>,<sup>1,2</sup> Jonah M. Levine,<sup>3</sup> Vivian P. Bykerk<sup>1,4</sup>,<sup>1,4</sup> Deanna Jannat-Khah,<sup>1,4</sup> Lisa A. Mandl<sup>1,2</sup>

<sup>1</sup>Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA

<sup>2</sup>Department of Medicine and Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA

<sup>3</sup>Hospital for Special Surgery, New York, New York, USA

<sup>4</sup>Department of Medicine, Weill Cornell Medical College, New York, New York, USA

**Correspondence to** Dr Medha Barbhैया, Division of Rheumatology, Hospital for Special Surgery, New York, NY 10021-4898, USA; barbhैया@hss.edu

**Handling editor** Josef S Smolen

**Contributors** All authors have made substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data; were involved in drafting the work or revising it critically for important intellectual content; provided final approval of the version published; and were in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding** MB is currently supported by the Rheumatology Research Foundation Investigator Award and the Barbara Volcker Centre for Women and Rheumatic Diseases at Hospital for Special Surgery. LAM received grant support from Regeneron Pharmaceuticals, and is an associate editor at *Annals of Internal Medicine*.

**Disclaimer** The funders had no role in study design, data collection, analysis, decision to publish or preparation of the manuscript.

**Competing interests** MB is currently supported by the Rheumatology Research Foundation Investigator Award and the Barbara Volcker Center for Women and Rheumatic Diseases at Hospital for Special Surgery. LAM received grant support from Regeneron Pharmaceuticals, and is an associate editor at *Annals of Internal Medicine*. The funders had no role in study design, data collection, analysis, decision to publish or preparation of the manuscript.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2021-220732>).



**To cite** Barbhैया M, Levine JM, Bykerk VP, *et al.* *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2021-220732

Received 6 May 2021

Accepted 10 June 2021

*Ann Rheum Dis* 2021;0:1–2. doi:10.1136/annrheumdis-2021-220732

#### ORCID iDs

Medha Barbhैया <http://orcid.org/0000-0002-6670-7696>

Vivian P. Bykerk <http://orcid.org/0000-0002-1219-3845>

#### REFERENCES

- 1 D'Silva KM, Jorge A, Cohen A, *et al.* COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases (SARDs) compared to the general population: a US multi-center comparative cohort study. *Arthritis Rheumatol* 2020.
- 2 Mok CC, Chan KH, Ho LY, *et al.* Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial. *Ann Rheum Dis* 2019;78:1663–8.
- 3 Ray P, Black S, Shinefield H, *et al.* Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. *Vaccine* 2011;29:6592–7.
- 4 Bechman K, Tweehuysen L, Garrood T, *et al.* Flares in rheumatoid arthritis patients with low disease activity: predictability and association with worse clinical outcomes. *J Rheumatol* 2018;45:1515–21.